November 5, 2025 — Leads & Copy —
LivaNova PLC (Nasdaq: LIVN) reported its third-quarter results for the period ended September 30, 2025, and has raised its full-year 2025 guidance. Third-quarter revenue reached $357.8 million, reflecting a 12.5% increase on a reported basis.
U.S. GAAP diluted earnings per share were $0.49, while adjusted diluted earnings per share reached $1.11. Net cash provided by operating activities totaled $85.1 million, with adjusted free cash flow at $62.0 million.
The company has raised its full-year 2025 revenue growth range by 50 basis points, expecting an 8.5% to 9.5% increase on a constant-currency basis and a 9.5% to 10.5% increase on an organic basis. The adjusted diluted earnings per share range has been raised by $0.10 at the midpoint, now projected at $3.80 to $3.90. Adjusted free cash flow is now expected to be in the range of $160 million to $180 million, an increase of $20 million at the midpoint.
LivaNova has initiated the commercial launch of the Essenz™ Perfusion System in China, the second-largest market for heart-lung machines after the United States. Donald Zurbay has been appointed to the Board of Directors and the Audit and Compliance Committee.
LivaNova will host a live audiocast on Wed., Nov. 5, 2025 at 1 p.m. London time (8 a.m. Eastern Time) that will be accessible at www.livanova.com/events.
Contact:
LivaNova PLC
Source: LivaNova PLC
